Oxidative stress in peripheral blood mononuclear cells from patients with Parkinson's disease: Negative correlation with levodopa dosage

Neurobiology of Disease

Volumn 23, Issue 1, 2006, Pages 36-43

  Prigione, Alessandro ^a   Begni, Barbara ^a   Galbussera, Alessio ^a,b   Beretta, Simone ^a,b   Brighina, Laura ^a,b   Garofalo, Rosanna ^a   Andreoni, Simona ^a   Piolti, Roberto ^b   Ferrarese, Carlo ^a,b,c  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b SAN GERARDO HOSPITAL   (Italy)

^c SCIENTIFIC INSTITUTE   (Italy)

Author keywords

Glutathione reductase; Levodopa; Oxidative stress; Parkinson's disease; PBMC; Reactive oxygen species

Indexed keywords

GLUTATHIONE REDUCTASE; LEVODOPA; REACTIVE OXYGEN METABOLITE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOPAMINERGIC SYSTEM; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; MALE; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PARKINSON DISEASE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

AGED; ANTIPARKINSON AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUTATHIONE REDUCTASE; HUMANS; LEUKOCYTES, MONONUCLEAR; LEVODOPA; MALE; MIDDLE AGED; OXIDATIVE STRESS; PARKINSON DISEASE; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 33745120510     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2006.01.013     Document Type: Article

References (48)

1. Alam Z.I., Jenner A., Daniel S.E., Lees A.J., Cairns N., Marsden C.D., Jenner P., and Halliwell B. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J. Neurochem. 69 (1997) 1196-1203
2. Amenta F., Bronzetti E., Cantalamessa F., El-Assouad D., Felici L., Ricci A., and Tayebati S.K. Identification of dopamine plasma membrane and vesicular transporters in human peripheral blood lymphocytes. J. Neuroimmunol. 117 (2001) 133-142
3. Andersen J.K. Oxidative stress in neurodegeneration: cause or consequence?. Nat. Med. 10 (2004) S18-S25 (Suppl.)
4. Barbanti P., Fabbrini G., Ricci A., Cerbo R., Bronzetti E., Caronti B., Calderaro C., Felici L., Stocchi F., Meco G., Amenta F., and Lenzi G.L. Increased expression of dopamine receptors on lymphocytes in Parkinson's disease. Mov. Disord. 14 (1999) 764-771
5. Blanchard V., Raisman-Vozari R., Vyas S., Michel P.P., Javoy-Agid F., Uhl G., and Agid Y. Differential expression of tyrosine hydroxylase and membrane dopamine transporter genes in subpopulations of dopaminergic neurons of the rat mesencephalon. Brain Res. Mol. Brain Res. 22 (1994) 29-38
6. Blandini F., Cosentino M., Mangiagalli A., Marino F., Samuele A., Rasini E., Fancellu R., Tassorelli C., Pacchetti C., Martignoni E., Riboldazzi G., Calandrella D., Lecchini S., Frigo G., and Nappi G. Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson's disease. The effect of dopaminergic treatment. J. Neural Transm. 111 (2004) 1017-1030
7. Bouhaddi M., Vuillier F., Fortrat J.O., Cappelle S., Henriet M.T., Rumbach L., and Regnard J. Impaired cardiovascular autonomic control in newly and long-term-treated patients with Parkinson's disease: involvement of l-dopa therapy. Auton. Neurosci. 116 (2004) 30-38
8. Buhmann C., Arlt S., Kontush A., Moller-Bertram T., Sperber S., Oechsner M., Stuerenburg H.J., and Beisiegel U. Plasma and CSF markers of oxidative stress are increased in Parkinson's disease and influenced by antiparkinsonian medication. Neurobiol. Dis. 15 (2004) 160-170
9. Caronti B., Tanda G., Colosimo C., Ruggieri S., Calderaro C., Palladini G., Pontieri F.E., and Di Chiara G. Reduced dopamine in peripheral blood lymphocytes in Parkinson's disease. NeuroReport 10 (1999) 2907-2910
10. Caronti B., Antonini G., Calderaro C., Ruggieri S., Palladini G., Pontieri F.E., and Colosimo C. Dopamine transporter immunoreactivity in peripheral blood lymphocytes in Parkinson's disease. J. Neural Transm. 108 (2001) 803-807
11. Carvey P.M., McGuire S.O., and Ling Z.D. Neuroprotective effects of D3 dopamine receptor agonists. Parkinsonism Relat. Disord. 7 (2001) 213-223
12. Chalimoniuk M., Stepien A., and Strosznajder J.B. Pergolide mesylate, a dopaminergic receptor agonist, applied with l-DOPA enhances serum antioxidant enzyme activity in Parkinson disease. Clin. Neuropharmacol. 27 (2004) 223-229
13. Cosentino M., Rasini E., Colombo C., Marino F., Blandini F., Ferrari M., Samuele A., Lecchini S., Nappi G., and Frigo G. Dopaminergic modulation of oxidative stress and apoptosis in human peripheral blood lymphocytes: evidence for a D1-like receptor-dependent protective effect. Free Radical Biol. Med. 36 (2004) 1233-1240
14. Dexter D.T., Carter C.J., Wells F.R., Javoy-Agid F., Agid Y., Lees A., Jenner P., and Marsden C.D. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52 (1989) 381-389
15. Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A., Olanow C.W., Tanner C., and Marek K. Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 351 (2004) 2498-2508
16. Gatto E.M., Riobo N.A., Carreras M.C., Chernavsky A., Rubio A., Satz M.L., and Poderoso J.J. Overexpression of neutrophil neuronal nitric oxide synthase in Parkinson's disease. Nitric Oxide 4 (2000) 534-539
17. Gaugitsch H.W., Prieschl E.E., Kalthoff F., Huber N.E., and Baumruker T. A novel transiently expressed, integral membrane protein linked to cell activation. Molecular cloning via the rapid degradation signal AUUUA. J. Biol. Chem. 267 (1992) 11267-11273
18. Gelb D.J., Oliver E., and Gilman S. Diagnostic criteria for Parkinson disease. Arch. Neurol. 56 1 (1999) 33-39
19. Good P.F., Hsu A., Werner P., Perl D.P., and Olanow C.W. Protein nitration in Parkinson's disease. J. Neuropathol. Exp. Neurol. 57 (1998) 338-342
20. Graham D.G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14 (1978) 633-643
21. Han S.K., Mytilineou C., and Cohen G. l-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress. J. Neurochem. 66 (1996) 501-510
22. Hoehn M.M., and Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology 17 5 (1967) 427-442
23. Jenner P. Oxidative stress in Parkinson's disease. Ann. Neurol. 53 Suppl. 3 (2003) S26-S36 (discussion S36-S38)
24. Jenner P. Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease. Neurology 63 (2004) S13-S22
25. Kitamura Y., Kakimura J., and Taniguchi T. Antiparkinsonian drugs and their neuroprotective effects. Biol. Pharm. Bull. 25 (2002) 284-290
26. Kostrzewa R.M., Kostrzewa J.P., and Brus R. Neuroprotective and neurotoxic roles of levodopa (l-DOPA) in neurodegenerative disorders relating to Parkinson's disease. Amino Acids 23 (2002) 57-63
27. Martignoni E., Blandini F., Godi L., Desideri S., Pacchetti C., Mancini F., and Nappi G. Peripheral markers of oxidative stress in Parkinson's disease. The role of l-DOPA. Free Radical Biol. Med. 27 (1999) 428-437
28. McKenna F., McLaughlin P.J., Lewis B.J., Sibbring G.C., Cummerson J.A., Bowen-Jones D., and Moots R.J. Dopamine receptor expression on human T- and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study. J. Neuroimmunol. 132 (2002) 34-40
29. Migliore L., Petrozzi L., Lucetti C., Gambaccini G., Bernardini S., Scarpato R., Trippi F., Barale R., Frenzilli G., Rodilla V., and Bonuccelli U. Oxidative damage and cytogenetic analysis in leukocytes of Parkinson's disease patients. Neurology 58 (2002) 1809-1815
30. Muftuoglu M., Elibol B., Dalmizrak O., Ercan A., Kulaksiz G., Ogus H., Dalkara T., and Ozer N. Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations. Mov. Disord. 19 (2004) 544-548
31. Musso N.R., Brenci S., Setti M., Indiveri F., and Lotti G. Catecholamine content and in vitro catecholamine synthesis in peripheral human lymphocytes. J. Clin. Endocrinol. Metab. 81 (1996) 3553-3557
32. Mytilineou C., Han S.K., and Cohen G. Toxic and protective effects of l-dopa on mesencephalic cell cultures. J. Neurochem. 61 (1993) 1470-1478
33. +-independent neutral amino acid transporter LAT1 during T-cell activation. Biochem. J. 358 (2001) 693-704
34. Olanow C.W., Agid Y., Mizuno Y., Albanese A., Bonucelli U., Damier P., De Yebenes J., Gershanik O., Guttman M., Grandas F., Hallett M., Hornykiewicz O., Jenner P., Katzenschlager R., Langston W.J., LeWitt P., Melamed E., Mena M.A., Michel P.P., Mytilineou C., Obeso J.A., Poewe W., Quinn N., Raisman-Vozari R., Rajput A.H., Rascol O., Sampaio C., and Stocchi F. Levodopa in the treatment of Parkinson's disease: current controversies. Mov. Disord. 19 (2004) 997-1005
35. Perry T.L., Yong V.W., Ito M., Foulks J.G., Wall R.A., Godin D.V., and Clavier R.M. Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of l-DOPA and carbidopa chronically. J. Neurochem. 43 (1984) 990-993
36. Quinn N., Parkes D., Janota I., and Marsden C.D. Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period. Mov. Disord. 1 (1986) 65-68
37. Rajda C., Dibo G., Vecsei L., and Bergquist J. Increased dopamine content in lymphocytes from high-dose l-Dopa-treated Parkinson's disease patients. Neuroimmunomodulation 12 (2005) 81-84
38. Ricci A., Bronzetti E., Mignini F., Tayebati S.K., Zaccheo D., and Amenta F. Dopamine D1-like receptor subtypes in human peripheral blood lymphocytes. J. Neuroimmunol. 96 (1999) 234-240
39. Sampaio-Maia B., Serrao M.P., and Soares-da-Silva P. Regulatory pathways and uptake of l-DOPA by capillary cerebral endothelial cells, astrocytes, and neuronal cells. Am. J. Physiol., Cell Physiol. 280 (2001) C333-C342
40. Sawada H., Ibi M., Kihara T., Urushitani M., Akaike A., Kimura J., and Shimohama S. Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress. Ann. Neurol. 44 (1998) 110-119
41. Schapira A.H. Neuroprotection and dopamine agonists. Neurology 58 (2002) S9-S18
42. Schapira A.H., Cooper J.M., Dexter D., Clark J.B., Jenner P., and Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54 (1990) 823-827
43. Slivka A., and Cohen G. Hydroxyl radical attack on dopamine. J. Biol. Chem. 260 (1985) 15466-15472
44. Sofic E., Lange K.W., Jellinger K., and Riederer P. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci. Lett. 142 (1992) 128-130
45. Takahashi N., Nagai Y., Ueno S., Saeki Y., and Yanagihara T. Human peripheral blood lymphocytes express D5 dopamine receptor gene and transcribe the two pseudogenes. FEBS Lett. 314 (1992) 23-25
46. Vitte J., Michel B.F., Bongrand P., and Gastaut J.L. Oxidative stress level in circulating neutrophils is linked to neurodegenerative diseases. J. Clin. Immunol. 24 (2004) 683-692
47. Yoshino H., Nakagawa-Hattori Y., Kondo T., and Mizuno Y. Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease. J. Neural Transm., Parkinson's Dis. Dement. Sect. 4 (1992) 27-34
48. Zeng B.Y., Pearce R.K., MacKenzie G.M., and Jenner P. Chronic high dose l-dopa treatment does not alter the levels of dopamine D-1, D-2 or D-3 receptor in the striatum of normal monkeys: an autoradiographic study. J. Neural Transm. 108 (2001) 925-941